Redcare Pharmacy posts 20% revenue rise and first international profit in Q2
Redcare Pharmacy N.V. reported a 20 % increase in second‑quarter revenue, reaching €853 million. The company's prescription‑drug (Rx) sales in the DACH region grew 34 % to €339 million, driven by a 58 % jump in Germany. Adjusted EBITDA rose to €30 million from €18 million a year earlier, with the EBITDA margin improving to 3.5 % from 2.6 %. The international segment posted a profit for the first time, confirming the firm's upgraded full‑year guidance of 15‑17 % revenue growth and 35‑43 % Rx‑sales growth. Active customers rose by half a million to 14.7 million, and order volumes were up 17 % year‑on‑year.
Entities: DACH region · European Union · Germany · Olaf Heinrich · Redcare Pharmacy · Redcare Pharmacy N.V. · Switzerland
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Redcare Pharmacy reaffirmed its 2026 full‑year guidance of 15‑17 % revenue growth and a 35‑43 % increase in German Rx sales. (Redcare Pharmacy grows strong at prescription drugs)
- [● 2 SOURCES] Adjusted EBITDA increased to €30 million, up from €18 million a year earlier. (Redcare Pharmacy grows strong at prescription drugs)
- [● 2 SOURCES] Redcare Pharmacy's second‑quarter revenue reached €853 million, up 20 % year‑on‑year. (Redcare Pharmacy grew strong at prescription drugs)
- [○ 1 SOURCE] First‑quarter adjusted EBITDA margin was 1.7 %. (Redcare Pharmacy: Umsatzsprung reicht noch nicht – Halbjahresbericht entscheidet über Profitabilität)
- [○ 1 SOURCE] Rx sales in the DACH region grew 34 % to €339 million, with German Rx sales up 58 %. (Redcare Pharmacy grows strong at prescription drugs)
- [○ 1 SOURCE] Projected 2026 adjusted EBITDA margin is 2.5‑3.0 %. (Redcare Pharmacy grows strong at prescription drugs)
- [○ 1 SOURCE] Adjusted EBITDA margin improved to 3.5 % from 2.6 % year‑on‑year. (Redcare Pharmacy grows strong at prescription drugs)
- [○ 1 SOURCE] A half‑year report is due at the end of July to assess profitability sustainability. (Redcare Pharmacy: Umsatzsprung reicht noch nicht – Halbjahresbericht entscheidet über Profitabilität)
- [● 2 SOURCES] Redcare raised its full‑year revenue growth guidance to 15‑17% and Rx‑sales growth guidance to 35‑43%.
- [● 2 SOURCES] Redcare Pharmacy's international segment posted a profit for the first time.
- [● 2 SOURCES] Rx sales in Germany grew 58% year‑on‑year.
- [● 2 SOURCES] Adjusted EBITDA increased to €30 million from €18 million a year earlier.